Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
0 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Solid Biosciences Inc.’s names, not what it holds today.
Patents granted
0
by type: not read, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
13
6 of them in 2025
Names they are printed under
3
its own name, a subsidiary
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name3 counted
Solid Biosciences Inc. its own name
named as the applicant on its applications, in US
6 publishedAavantiBio, Inc. a subsidiary
US, as the owner printed on each patent
5 publishedAavantiBio, Inc. a subsidiary
named as the applicant on its applications, in US
2 published
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jun 26, 2025 | 2025/0205365 | METHODS AND COMPOSITIONS FOR TREATING RBM20 RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR | Pharmaceuticals | AavantiBio, Inc. |
| Jun 19, 2025 | 2025/0195694 | METHODS AND COMPOSITIONS FOR TREATING TNNT2 RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR | Pharmaceuticals | AavantiBio, Inc. |
| Feb 6, 2025 | 2025/0041453 | METHODS AND COMPOSITIONS FOR TREATING BAG-3 RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR | Pharmaceuticals | AavantiBio, Inc. |
| Feb 6, 2025 | 2025/0041452 | METHODS AND COMPOSITIONS FOR TREATING MYBPC3 RELATED HYPERTROPHIC CARDIOMYOPATHY WITH A VIRAL VECTOR | Pharmaceuticals | AavantiBio, Inc. |
| Jan 16, 2025 | 2025/0020684 | GRADIENT ULTRACENTRIFUGATION AUTOMATED COLLECTOR | Measurement | AavantiBio, Inc. |
| Jan 16, 2025 | 2025/0019722 | COMPOSITIONS COMPRISING KOZAK SEQUENCES SELECTED FOR ENHANCED EXPRESSION | Biotechnology | AavantiBio, Inc. |
| Oct 24, 2024 | 2024/0350674 | TREATMENT OF MUSCULAR DYSTROPHY | Pharmaceuticals | Solid Biosciences Inc. |
| Aug 8, 2024 | 2024/0261437 | MODIFIED AAV CAPSIDS AND USES THEREOF | Biotechnology | Solid Biosciences Inc. |
| Jun 13, 2024 | 2024/0191251 | RECOMBINANT HERPESVIRALES VECTOR | Biotechnology | Solid Biosciences Inc. |
| Feb 22, 2024 | 2024/0058477 | METHODS AND COMPOSITIONS FOR TREATMENT OF FRIEDREICH'S ATAXIA | Pharmaceuticals | AavantiBio, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 6 · Biotechnology 3 · Measurement 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.